BRIEF published on 09/18/2026 at 07:35, 1 day 14 hours ago MaaT Pharma Faces Setback with CHMP Decision on MaaT013 Clinical Trial MaaT013 CHMP Decision PHOENIX Study Regulatory Plan
PRESS RELEASE published on 09/18/2026 at 07:30, 1 day 14 hours ago Inside Information / Other news releases MaaT Pharma provides update on CHMP negative opinion for MaaT013 (Xervyteg) development plan, focusing on Phase 3 trial PHOENIX. FDA support noted for potential patient enrollment in H1 2027 FDA Phase 3 Trial MaaT Pharma CHMP MaaT013
BRIEF published on 09/15/2026 at 07:35, 4 days 14 hours ago MaaT Pharma: unfavorable vote by the CHMP for MaaT013 MaaT Pharma MaaT013 CHAMP Negative Vote Randomized Trial
PRESS RELEASE published on 09/15/2026 at 07:30, 4 days 14 hours ago Inside Information / Other news releases MaaT Pharma receives negative CHMP trend vote for MaaT013 (Xervyteg) conditional marketing authorization application in Europe. Company vows to explore options for patient access MaaT Pharma CHMP Clinical Benefit Xervyteg Negative Trend
BRIEF published on 07/24/2026 at 12:17, 1 month 26 days ago Invus Public Equities reduces its stake in MAAT PHARMA Voting Rights Threshold Crossing Transfer Of Shares MaaT Pharma Invus
BRIEF published on 07/02/2026 at 18:35, 2 months 17 days ago Current status of MaaT Pharma shares and voting rights Euronext Paris Voting Rights Biotechnology Actions MaaT Pharma
BRIEF published on 06/30/2026 at 13:13, 2 months 19 days ago MaaT Pharma's Marketing Application for MaaT013 Faces Setback Graft-versus-Host Disease MaaT Pharma CHMP Decision Marketing Application Re-examination Appeal
PRESS RELEASE published on 06/30/2026 at 13:08, 2 months 19 days ago Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): Under review First Berlin Equity Research updates rating and price target for MaaT Pharma SACA after CHMP's negative opinion on MAA for MaaT013 in aGvHD First Berlin Equity Research CHMP AGvHD MaaT Pharma SACA MAA
BRIEF published on 06/26/2026 at 07:35, 2 months 23 days ago MaaT Pharma to Challenge Negative CHMP Verdict for MaaT013 Microbiome Ecosystem Therapies MaaT Pharma Acute Graft-versus-Host Disease CHMP Re-examination MaaT013 Xervyteg
PRESS RELEASE published on 06/26/2026 at 07:30, 2 months 23 days ago Inside Information / Other news releases MaaT Pharma to request re-examination by CHMP after negative opinion on MaaT013 for acute Graft-versus-Host Disease treatment. Company plans second opinion during September 2026 session Graft-versus-Host Disease MaaT Pharma CHMP MaaT013 Re-examination
Published on 09/19/2026 at 00:55, 21 hours 14 minutes ago Gossan Resources Announces Changes to Board and Management
Published on 09/18/2026 at 23:50, 22 hours 19 minutes ago Mako Mining Announces Equity Incentive Grants
Published on 09/18/2026 at 22:00, 1 day ago Silver Tiger Announces Results of Annual and Special Meeting
Published on 09/18/2026 at 20:35, 1 day 1 hour ago Only 11% of Marketers Expect Google Search to Be Their Customers' Main Starting Point in Two Years
Published on 09/18/2026 at 14:30, 1 day 7 hours ago AIAI Holdings to Obtain a Controlling Position in Messier 42 Marketing Agreement
Published on 09/19/2026 at 16:40, 5 hours 29 minutes ago 2026 Cross-Strait (Kunshan) Mid-Autumn Lantern Festival Opens
Published on 09/19/2026 at 13:15, 8 hours 54 minutes ago Eurobattery Minerals AB has received information regarding court judgment and criminal suspicion concerning the CEO
Published on 09/19/2026 at 07:30, 14 hours 39 minutes ago Hong Kong sets out initiatives to secure long-term development of pillar industries
Published on 09/18/2026 at 18:44, 1 day 3 hours ago EQS-Adhoc: Enapter AG announces preliminary, unaudited figures for the first half of 2026 and restructures its US sales operations – one-off expense of EUR 17 million
Published on 09/18/2026 at 18:34, 1 day 3 hours ago Disclosure of transactions in own shares from September 14 to September 18, 2026
Published on 09/17/2026 at 17:40, 2 days 4 hours ago Eiffage wins a second contract, as part of the NSORe joint venture, for an offshore converter station in Germany
